{"entity":{"id":"al2846","kind":"drug","name":"AL2846","aka":[],"tldr":"AL2846 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for thyroid cancer, aimed at MET and RET.","summary":"AL2846 is a small-molecule drug developed by Chia Tai Tianqing Pharmaceutical. Its targets are MET, RET and KIT (the sponsor names c-MET, c-KIT, VEGFR1, RET). The sponsor states: A multi-target tyrosine kinase inhibitor capsule with significant inhibitory effects on c-MET, c-KIT, VEGFR1 and RET. ClinicalTrials.gov describes the intervention as: AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06860971 (A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma), in thyroid cancer. The largest, NCT06860971, plans to enrol 144 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AL2846","url":"https://clinicaltrials.gov/search?intr=AL2846"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":[],"targets":["met","ret","kit"],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06860971"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"A multi-target tyrosine kinase inhibitor capsule with significant inhibitory effects on c-MET, c-KIT, VEGFR1 and RET.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/al2846/","neighbours":{"cancer":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/"}]}}